Dr Atul Malhotra, an Honorary Clinical Associate in the Neurodevelopment and Neuroprotection Research Group at Hudson Institute

Associate Professor Atul Malhotra, MBBS, MD, DNB, FRACP, PhD

A/Professor Atul Malhotra is a consultant neonatologist at Monash Newborn, Monash Children’s Hospital, and Kathleen Tinsley Senior Research Fellow at The Ritchie Centre, Hudson Institute of Medical Research and Department of Paediatrics, Monash University.

His clinical research interests focus on improving respiratory and neurological outcomes of high-risk infants. He is the lead site investigator of a large NHMRC funded trial on neurodevelopment of the preterm infant, and head of the Early Neurodevelopment Clinic (for early detection of cerebral palsy) at Monash Children’s Hospital. He has been instrumental in the translation of a number of preclinical therapies from the laboratory to the clinic. He was the clinical lead of the team who conducted the first-in-human trial of placental stem cells in neonatal chronic lung disease.

His basic science research interests include understanding and treating brain injury related to high risk perinatal conditions. He completed his PhD, titled, “Novel strategies for early detection and treatment of fetal growth restriction related brain injury” with Professor Suzie Miller and Professor Graham Jenkin at the Hudson Institute inn 2019. He has been the recipient of multiple RACP fellowships; and is a chief investigator on a number of NHMRC and other competitive grants for his research work. He continues to be involved in translational science work with the Neurodevelopment and Neuroprotection, and Cell Therapy and Regenerative Medicine Groups, and is currently leading a clinical trial of umbilical cord blood derived cells in extremely premature infants.

He is also heavily involved in medical education and simulation activities both at Monash Children’s Hospital and in low and middle-income countries overseas. In particular, he regularly travels to India to facilitate simulation based education workshops for local health workers in obstetric and neonatal emergencies (onesimeducation.com). This work has been supported by the Bill and Melinda Gates Foundation and the RACP.

Selected publications

  • Aridas JDS, Yawno T, Sutherland AE, Nitsos I, Ditchfield M, Wong FY, Hunt RW, Fahey MC, Malhotra A, Wallace EM, Jenkin G, Miller SL (2018) Systemic and transdermal melatonin administration prevents neuropathology in response to perinatal asphyxia in newborn lambs. J Pineal Res 2018 May; 64(4):e12479.

  • Lim R*, Malhotra A*, Tan JL, Chan ST, Lau S, Zhu D, Mockler JC, Wallace EM (2018) First-in-human administration of allogeneic amnion cells in premature infants with bronchopulmonary dysplasia: a safety study. Stem Cells Transl Med 2018 Sep;7(9):628-635.

  • Malhotra A, Castillo-Melendez M, Allison BJ, Sutherland AE, Nitsos I, Pham Y, Alves de Alencar Rocha AK, Fahey MC, Polglase GR, Jenkin G, Miller SL (2018) Neuropathology as a consequence of neonatal ventilation in premature growth restricted lambs. Am J Physiol Regul Integr Comp Physiol 2018 Dec; 315(6): R1183-1194.

  • Baker EK, Malhotra A, Lim R, Jacobs SE, Hooper SB, Davis PG, Wallace EM (2019) Human amnion cells for the prevention of bronchopulmonary dysplasia. a protocol for a phase 1 dose escalation study. BMJ Open 2019;9:e026265.

  • Malhotra A*, Allison BJ*, Castillo-Melendez M, Jenkin G, Polglase GR, Miller SL (2019) Neonatal morbidities of fetal growth restriction: pathophysiology and impact. Front Endocrinol 2019;10:55.